"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA grants accelerated approval to pemigatinib (Pemazyre) for cholangiocarcinoma with an FGFR2 rearrangement or fusion

FDA grants accelerated approval to pemigatinib (Pemazyre) for cholangiocarcinoma with an FGFR2 rearrangement or fusion

21 Apr 2020 9:06 AM | Nathan Strunk (Administrator)

The Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software